were measured by qRT-PCR and normalized to miR-16.
upregulated (miR-19b, miR-21) , two were downregulated (miR-25, miR-183) in cancer patients. Four miRNAs (miR-19b, miR-126, miR-25, miR-205) were found to be differentially regulated in SCC patients when compared to healthy controls. In AC patients only two miRNAs (miR-19b, miR-183) were differently expressed. Thus, cancer subtypes have different input into overall picture.
Receiver Operating Characteristic (ROC) curve analysis of differentially expressed miRNAs in total study population and subtype-based groups showed that miR-19b has highest predictive value for total population and SCC patients, while miR-183 was more effective in discriminating patients with AC. All miRNAs except miR-21 showed strong bias towards one of the subtypes. Presumably a combination of miRNAs with opposite bias should provide a more potent diagnostic tool for cancer detection in total population than individual miRNAs or panels of miRNAs that are specific to one cancer subtype. Indeed, stepwise binary logistic regression has identified the combination of miR-19b and miR-183 to be a strong prediction of disease in total population and yielded a solid increase in AUC: 0,990 (miR-19b+miR-183) versus 0,806 (miR-19b) or 0,924 (miR-183) . This combination can be used to identify lung cancer with 94.7% sensitivity and 95.2% specificity.
Thus, biological aspects such as tumor genetics and phenotype, stage of disease, response to therapy, and other meaningful tumor properties of such heterogeneous malignancies as LC can interfere with contents and composition of cell-free miRNA pool.
Wide profiling of circulating miRNAs will specify biomarkers of LC phenotypes and improve non/less-invasive LC diagnostics. We studied the association of polymorphic markers Arg72Pro
and Gln157Lys of TP53 gene with the risk of nonsmall cell lung cancer (NSCLC) in patients from the Moscow region. Our study included 88 patients with NSCLC, 160 healthy persons as a control for Arg72Pro and 60 healthy persons as a control for Gln157Lys.
We used PCR-RLFP analysis to identify the alleles of the polymorphic markers.
We observed higher frequencies of the markers predisposition 
Results:
Twelve patients (54.5%) achieved a pathological complete response (pCR) (Ch1+ Ch2 C61G. 3/4 patients with BRCA1 185delAG mutation had BRCA1 C61G mutation. BRCA1 LOH was detected in 1/22 (4.5%) patient.
All patients with BRCA1 5382insC mutation achieved a pCR (p = 0.01). All patients with BRCA1 185delAG mutation and BRCA1 C61G mutation had residual disease (0.04 and 0.1, accordingly).
Conclusion:
BRCA1 5382insC somatic mutation is associated with good response to neoadjuvant platinum based chemother- A1" (Germany) and slidescanner ''MiraxMidiZeiss" (Germany).
Metastatic lesion was detected in regional lymph nodes.
Immunohistochemical study was performed according to stan- The following primary antibodies were used: mouse monoclonal anti-human CD68 (BD Biosciences) and rabbit polyclonal antistabilin-1 or RS1 (marker of M2 macrophages).
Results:
The highest expression of CD68 in the inflammatory cell infiltrate was detected more frequently in areas with soft fibrous stroma (54%) or the so-called ''maximum stromal-andparenchymal relationship" (79%) in patients with breast cancer. 
